(Reuters) - GlaxoSmithKline said on Tuesday its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned ...
LONDON -Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer ...
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. The sale is part of a broader scheme by GSK and Pfizer to reduce their holdings in the consumer health venture ...
Considerable on MSN
GSK buys Rapt in $2.2B deal
GSK agreed to acquire Rapt Therapeutics for $2.2 billion on Tuesday, a move that ...
Emma Walmsley, the CEO who led the U.K. drugmaker GSK through the Covid-19 pandemic and the transformative spinoff of its consumer-health brands, will step down at the end of the year, the company ...
In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results